American Heart Journal
Volume 151, Issue 6 , Pages 1131-1138 , June 2006

Argatroban: Update

  • Robert W. Yeh, MD
    • ,
  • Ik-Kyung Jang, MD, PhD

      Affiliations

    • Corresponding Author InformationReprint requests: Ik-Kyung Jang, MD, PhD, Cardiology Division, Massachusetts General Hospital, Gray/Bigelow 800, 55 Fruit Street, Boston, MA 02114.

Received 25 March 2005 ,Accepted 1 September 2005.

References 

  1. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small molecule, direct thrombin inhibitor. Semin Thromb Hemost. 1997;23:503–516
  2. Berry CN, Girardot C, Lecoffre C, et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost. 1994;72:381–386
  3. Lunven C, Gauffeny C, Lecoffre C, et al. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost. 1996;75:154–160
  4. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318–329
  5. Tran JQ, Di Cicco RA, Sheth SB, et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999;39:513–519
  6. Swan SK, St. Peter JV, Lambrecht LJ, et al. Comparison of anticoagulation effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy. 2000;20:756–770
  7. Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol. 1993;21:1039–1047
  8. Jang IK, Gold HK, Leinbach RC, et al. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res. 1990;67:1552–1561
  9. Jang IK, Gold HK, Ziskind AA, et al. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation. 1989;81:219–225
  10. Jang IK, Gold HK, Leinbach RC, et al. Persistent inhibition of arterial thrombosis by a 1-hour intravenous infusion of argatroban, a selective thrombin inhibitor. Coron Artery Dis. 1992;3:407–414
  11. Yasuda T, Gold HK, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion, and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol. 1990;16:714–722
  12. Yamada K, Tsuji J, Kimura S, et al. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model. Thromb Res. 2003;109:55–64
  13. Morris DC, Zhang L, Zheng GZ, et al. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke. 2001;32:2635–2640
  14. Jang IK, Brown DR, Giugliano RP, et al. A multi-center, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: myocardial infarction with novastan and tPA (MINT) study. J Am Coll Cardiol. 1999;33:1880–1885
  15. Vermeer F, Vahanian A, Fels PW, et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study. J Thromb Thrombolysis. 2000;10:233–240
  16. Behar S, Hod H, Kaplinski E. Argatroban versus heparin as adjuvant therapy to thrombolysis for acute myocardial infarction: safety considerations—ARGAMI-2 Study. Circulation. 1998;98(Suppl 17):I453–I454
  17. Cody RJ. Results from late breaking clinical trials session at ACC'97. J Am Coll Cardiol. 1997;30:1–7
  18. Lewis BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57:177–184
  19. Jang IK, Lewis BE, Matthai WH, et al. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, non-randomized pilot study. J Thromb Thrombolysis. 2004;18:31–37
  20. Cox DS, Kleiman NS, Boyle DA, et al. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention. J Clin Pharmacol. 2004;44:981–990
  21. Ohteki H, Furukawa K, Ohnishi H, et al. Clinical experience of argatroban for anticoagulation in cardiovascular surgery. Jpn J Thorac Cardiovasc Surg. 2000;48:39–46
  22. Ohno J, Higashidate M, Yokosuka T. Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery. Heart Vessels. 2003;18:40–42
  23. Cannon MA, Butteroworth J, Riley RD, et al. Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. Ann Thorac Surg. 2004;77:711–713
  24. Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med. 1999;50:129–147
  25. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502–507
  26. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106:629–635
  27. Walenga JM, Jeske WP, Fasanella AR, et al. Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 1999;(5 Suppl 1):S21–S27
  28. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849–1856
  29. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838–1843
  30. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med. 2004;32:976–980
  31. Matthai WH, Hursting MJ, Lewis BE, et al. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res. 2005;116:121–126
  32. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286–1292
  33. Refaai MA, Laposata M, Van Cott EM. Clinical significance of a borderline titer in a negative ELISA test for heparin-induced thrombocytopenia. Am J Clin Pathol. 2003;119:61–65
  34. Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost. 1997;23:531–534
  35. LaMonte MP, Marshall LN, Wang DZ, et al. Argatroban anticoagulation in patients with acute ischemic stroke. Stroke. 2004;35:1677–1682
  36. Sugg RM, Pan JK, Uchino K, et al. Tpa ARgatroban sTroke Study (TARTS). Stroke. 2005;36:447
  37. Luzzatto G, Bertoli M, Cella G, et al. Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res. 1998;89:115–122
  38. Murray PT, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int. 2004;66:2446–2453
  39. Tang IY, Cox DS, Patel K, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2005;39:231–236
  40. Argatroban manufacturer's website. http://www.argatroban.com (15 March 2005).
  41. Williamson DR, Boulanger I, Tardiff M, et al. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy. 2004;24:409–414
  42. Reichert MG, MacGregor DA, Kincaid EH, et al. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother. 2003;37:652–654
  43. Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost. 2001;85:435–440
  44. Harder S, Graff J, Klinkhardt U, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time. Thromb Haemost. 2004;91:1137–1145
  45. Young G, Yonekawa KE, Nakagawa P, et al. Recombinant factor VIIa reverses the anticoagulant effects of argatroban, bivalirudin, fondaparinux, enoxaparin, and heparin as assessed ex vivo by thromboelastography. Blood. 2004;104:Abstract
  46. Malherbe S, Tsui BC, Stobart K, et al. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology. 2004;100:443–445

 Dr Jang has received research grant and/or consultancy fees from Boston Scientific Corp, Guidant, GlaxoSmithKline, and Mitsubishi-Pharma.

PII: S0002-8703(05)00846-X

doi: 10.1016/j.ahj.2005.09.002

American Heart Journal
Volume 151, Issue 6 , Pages 1131-1138 , June 2006

Article Tools

* Image Usage & Resolution